Nothing Special   »   [go: up one dir, main page]

CO6511253A2 - Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma - Google Patents

Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma

Info

Publication number
CO6511253A2
CO6511253A2 CO12046741A CO12046741A CO6511253A2 CO 6511253 A2 CO6511253 A2 CO 6511253A2 CO 12046741 A CO12046741 A CO 12046741A CO 12046741 A CO12046741 A CO 12046741A CO 6511253 A2 CO6511253 A2 CO 6511253A2
Authority
CO
Colombia
Prior art keywords
recombinant
vaccine
produce
aviar
paramixovirus
Prior art date
Application number
CO12046741A
Other languages
English (en)
Spanish (es)
Inventor
Michel Bublot
Teshome Mebatsion
Joyce Anita Pritchard
Egbert Mundt
Original Assignee
Merial Ltd
Univ Georgia Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Univ Georgia Res Found filed Critical Merial Ltd
Publication of CO6511253A2 publication Critical patent/CO6511253A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2999/00—Further aspects of viruses or vectors not covered by groups C12N2710/00 - C12N2796/00 or C12N2800/00
    • C12N2999/007—Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
CO12046741A 2009-08-21 2012-03-20 Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma CO6511253A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23591209P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
CO6511253A2 true CO6511253A2 (es) 2012-08-31

Family

ID=43027613

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12046741A CO6511253A2 (es) 2009-08-21 2012-03-20 Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma

Country Status (19)

Country Link
US (1) US8486418B2 (fr)
EP (2) EP2467158B1 (fr)
JP (2) JP6221167B2 (fr)
KR (1) KR101745029B1 (fr)
CN (2) CN102573901B (fr)
BR (1) BR112012003837B8 (fr)
CA (1) CA2771540C (fr)
CL (2) CL2012000447A1 (fr)
CO (1) CO6511253A2 (fr)
ES (2) ES2622087T3 (fr)
HU (2) HUE053237T2 (fr)
MX (1) MX2012002114A (fr)
PL (2) PL3210622T3 (fr)
PT (2) PT2467158T (fr)
RU (2) RU2016112465A (fr)
SG (2) SG178523A1 (fr)
UA (1) UA110328C2 (fr)
WO (1) WO2011022656A2 (fr)
ZA (1) ZA201201245B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111172120A (zh) 2013-03-14 2020-05-19 西奈山伊坎医学院 新城疫病毒及其用途
US20140341950A1 (en) * 2013-05-15 2014-11-20 University Of Georgia Research Foundation, Inc. Recombinant avian paramyxovirus vaccine and method for making and using thereof
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
CN104195116B (zh) * 2014-08-13 2018-03-06 吉林大学 一种表达鹅细小病毒vp3基因的重组新城疫病毒及其构建方法
WO2016027135A1 (fr) * 2014-08-22 2016-02-25 Idisa Innovacion, S.A. De C.V. Vaccin émulsionné pour obtenir des formulations d'immunoglobulines igy concentrées, procédés et utilisations de celles-ci
MX2017005687A (es) 2014-11-03 2017-08-21 Merial Inc Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
JOP20190256A1 (ar) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
JP7408098B2 (ja) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド Ｒｎａポリメラーゼバリアント
CN108315486A (zh) * 2018-04-11 2018-07-24 张薇 一种用于检测罗湖病毒的环介导等温扩增引物组及试剂盒
CN112739359A (zh) * 2018-07-13 2021-04-30 西奈山伊坎医学院 Apmv及其用于治疗癌症的用途
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
CN112111467B (zh) * 2020-09-27 2021-06-22 湖北省农业科学院畜牧兽医研究所 一种基因vii型新城疫标记疫苗株及其制备方法与应用
CN116068196A (zh) * 2022-10-26 2023-05-05 新疆农业大学 一种检测禽副黏病毒4型血清抗体的elisa方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0575491B1 (fr) 1991-03-07 2003-08-13 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
EP0974660A1 (fr) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Clones infectieux du virus de la maladie de Newcastle, vaccins et analyses diagnostiqués
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
RU2162341C1 (ru) * 2000-03-06 2001-01-27 Открытое акционерное общество "ВЫМПЕЛ КОМПЛЕКС" Сухая живая вакцина против ньюкаслской болезни и способ ее получения
JP4791651B2 (ja) * 2000-05-18 2011-10-12 株式会社ディナベック研究所 外来遺伝子導入用パラミクソウイルスベクター
PT1383795E (pt) * 2000-11-02 2007-04-30 Intervet Int Bv Mutante da nucleoproteína do vírus da doença de newcastle recombinante como vacina marcadora
DE602004013331T2 (de) 2003-07-24 2009-07-16 Merial Ltd. Vakzin-formulierungen mit einer öl-in-wasser-emulsion
CN101421294A (zh) * 2006-03-15 2009-04-29 英特威国际有限公司 表达禽流感病毒的h5血凝素的重组新城疫病毒
JP2009529861A (ja) * 2006-03-15 2009-08-27 インターベツト・インターナシヨナル・ベー・ベー 鳥インフルエンザウイルスのｈ５ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス
EP1834651A1 (fr) * 2006-03-15 2007-09-19 Universiteit Gent Nouvelles compositions de vaccins et procédés de préparation de vaccins pour des maladies vétérinaires
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
WO2010115133A2 (fr) * 2009-04-03 2010-10-07 Merial Limited Vaccins aviaires transportés par le virus de la maladie de newcastle

Also Published As

Publication number Publication date
MX2012002114A (es) 2012-08-08
CN102573901A (zh) 2012-07-11
ES2867457T3 (es) 2021-10-20
US20110081374A1 (en) 2011-04-07
CL2015002175A1 (es) 2016-04-22
JP2013502225A (ja) 2013-01-24
CA2771540C (fr) 2019-01-15
JP6221167B2 (ja) 2017-11-01
CN105331633A (zh) 2016-02-17
EP3210622A3 (fr) 2017-11-29
BR112012003837A2 (pt) 2016-11-16
CN102573901B (zh) 2015-11-25
SG10201405123WA (en) 2014-12-30
ZA201201245B (en) 2012-10-31
RU2012110576A (ru) 2013-09-27
EP3210622A2 (fr) 2017-08-30
EP2467158A2 (fr) 2012-06-27
WO2011022656A2 (fr) 2011-02-24
JP2016041079A (ja) 2016-03-31
US8486418B2 (en) 2013-07-16
HUE053237T2 (hu) 2021-06-28
BR112012003837B1 (pt) 2021-04-20
HUE033886T2 (en) 2018-01-29
EP3210622B1 (fr) 2020-12-16
PL2467158T3 (pl) 2017-07-31
SG178523A1 (en) 2012-03-29
WO2011022656A3 (fr) 2011-05-05
RU2016112465A3 (fr) 2020-01-28
UA110328C2 (en) 2015-12-25
RU2592544C2 (ru) 2016-07-20
KR20120059570A (ko) 2012-06-08
KR101745029B1 (ko) 2017-06-08
RU2016112465A (ru) 2018-11-27
PT3210622T (pt) 2021-03-03
CL2012000447A1 (es) 2012-08-31
EP2467158B1 (fr) 2017-01-25
PL3210622T3 (pl) 2021-06-28
CA2771540A1 (fr) 2011-02-24
PT2467158T (pt) 2017-05-04
BR112012003837B8 (pt) 2022-10-18
ES2622087T3 (es) 2017-07-05

Similar Documents

Publication Publication Date Title
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
MX2016011686A (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
CL2009000190A1 (es) Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.
EA202090994A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
NZ609903A (en) Expression vector for high level expression of recombinant proteins
UY33897A (es) Inhibidores del virus de la hepatitis c
MX2014007516A (es) Procesos que utilizan vlps con capsides resistentes a hidrolasas.
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
MD4481C1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
CO2017005830A2 (es) Composiciones de vacuna para el virus del dengue
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
WO2011119716A3 (fr) Mutations de gamme d'hôtes du flavivirus et leurs utilisations
EA201500837A1 (ru) Парвовирус свиней 5в, способы применения и вакцина
CO6670515A2 (es) Vectores de parapoxvirus
CL2012003737A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterologo derivado de un virus del moquillo canino; procedimiento para preparar dicho virus; composicion inmunogénica que comprende dicho virus; uso de dicho virus para tratar animal contra enfermedad del moquillo canino.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
CL2011002884A1 (es) Plasmido que comprende secuencias del genoma de virus gflv, celula que comprende dichas construcciones moleculares, y procedimiento para conferir resistencia y saneamiento al virus de la hoja en abanico de la vid (gflv) en vides no transgenicas.
EP2501405A4 (fr) Compositions, procédés et utilisations pour des éléments de poxvirus dans des constructions de vaccins
WO2010147971A3 (fr) Vecteur viral modifié par il23 pour vaccins recombinants et traitement de tumeurs